NEW YORK, Jan. 22, 2019 /PRNewswire/ --
About this marketDevelopment of gene therapy to drive growth in the market. The advances of regenerative medicines in the clinical phases are expected to fuel growth of the global hemoglobinopathies treatment market. Technavio's analysts have predicted that the hemoglobinopathies treatment market will register a CAGR of almost 11% by 2023.Read the full report: https://www.reportlinker.com/p05724821 Market OverviewStrong pipeline and expected approvals of late-stage moleculeThe market is witnessing an acute lack of approved therapies, these late-stage pipeline molecules are expected to gain momentum during the forecast period, which will fuel the market growth.Product recalls and tedious drug approval processThe strict regulations for providing the marketing approval for therapeutics that are being developed for the treatment of hemoglobinopathies is likely to pose a threat to the market.For the detailed list of factors that will drive and challenge the growth of the hemoglobinopathies treatment market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Medunik USA and Novartis the competitive environment is quite intense. Factors such as the strong pipeline and expected approvals of late-stage molecule and the development of gene therapy, will provide considerable growth opportunities to hemoglobinopathies treatment manufactures. ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik USA, and Novartis are some of the major companies covered in this report.Read the full report: https://www.reportlinker.com/p05724821 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
About this marketDevelopment of gene therapy to drive growth in the market. The advances of regenerative medicines in the clinical phases are expected to fuel growth of the global hemoglobinopathies treatment market. Technavio's analysts have predicted that the hemoglobinopathies treatment market will register a CAGR of almost 11% by 2023.Read the full report: https://www.reportlinker.com/p05724821 Market OverviewStrong pipeline and expected approvals of late-stage moleculeThe market is witnessing an acute lack of approved therapies, these late-stage pipeline molecules are expected to gain momentum during the forecast period, which will fuel the market growth.Product recalls and tedious drug approval processThe strict regulations for providing the marketing approval for therapeutics that are being developed for the treatment of hemoglobinopathies is likely to pose a threat to the market.For the detailed list of factors that will drive and challenge the growth of the hemoglobinopathies treatment market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including Medunik USA and Novartis the competitive environment is quite intense. Factors such as the strong pipeline and expected approvals of late-stage molecule and the development of gene therapy, will provide considerable growth opportunities to hemoglobinopathies treatment manufactures. ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik USA, and Novartis are some of the major companies covered in this report.Read the full report: https://www.reportlinker.com/p05724821 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
View original content:http://www.prnewswire.com/news-releases/the-hemoglobinopathies-treatment-market-will-register-a-cagr-of-almost-11-by-2023-300782055.html
SOURCE Reportlinker
